<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296488</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(I)-20170089</org_study_id>
    <nct_id>NCT03296488</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of NALDEBAIN for the Treatment of Post-Laparotomy Surgery</brief_title>
  <official_title>A Randomized Controlled Trial to Compare the Efficacy and Safety of NALDEBAIN With Intravenous Patient-Controlled Analgesia With Fentanyl for the Treatment of Post-Laparotomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of single doses&#xD;
      of intramuscular NALDEBAIN on patients scheduled to undergo elective laparotomy. This will be&#xD;
      performed by administering NALDEBAIN pre-operatively to subjects scheduled to undergo&#xD;
      elective laparotomy, and assessing the safety and efficacy of the drug compared to PCA with&#xD;
      fentanyl. The study will demonstrate whether single use of NALDEBAIN is noninferior to PCA&#xD;
      with fentanyl or not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening (Days -30 to -1) (All Study Subjects)&#xD;
&#xD;
      The nature of the study, as well as the potential risks and benefits associated with study&#xD;
      participation, will be fully explained to all potential subjects. The following will then be&#xD;
      obtained:&#xD;
&#xD;
        -  Informed consent.&#xD;
&#xD;
        -  Demographic information, including sex, age, BMI and type of surgery.&#xD;
&#xD;
        -  Vital signs, including temperature, respiratory rate, blood pressure and heart rate.&#xD;
&#xD;
        -  Medical history, including medication use and history of allergy.&#xD;
&#xD;
        -  Physical examination.&#xD;
&#xD;
        -  Laboratory testing, including hematological and biochemical tests, and urinalysis.&#xD;
&#xD;
        -  ECG and X-ray.&#xD;
&#xD;
      Study Day -1 (All Eligible Subjects)&#xD;
&#xD;
        -  Eligible subjects will be required to check into the clinical site before surgery (Day&#xD;
           -1). The following procedures will be performed upon check-in:&#xD;
&#xD;
             -  Review inclusion/exclusion criteria&#xD;
&#xD;
             -  Randomization&#xD;
&#xD;
             -  Review of concomitant medications&#xD;
&#xD;
             -  Review of adverse events&#xD;
&#xD;
        -  Additional laboratory tests will be requested as needed deciding by the investigator.&#xD;
&#xD;
        -  All eligible subjects will hospitalize and be randomized into one of two treatment&#xD;
           groups:&#xD;
&#xD;
             -  Group 1 - Intramuscular NALDEBAIN.&#xD;
&#xD;
             -  Group 2 - Intravenous PCA with fentanyl. Group 1 will receive single dose of&#xD;
                NALDEBAIN (150 mg Nalbuphine Sebacate) intramuscularly 24±12 hours before surgery.&#xD;
&#xD;
      Group 2 will receive intravenous patient-controlled analgesia with fentanyl through 48 hours&#xD;
      after surgery.&#xD;
&#xD;
        -  Pain assessment: group 1 and 2 will rate their pain intensity using a VAS pain scale&#xD;
           prior dosing or at Day -1 respectively.&#xD;
&#xD;
        -  Brief Pain Inventory (BPI) will be evaluated at Day -1.&#xD;
&#xD;
        -  Vital signs will be checked prior to dosing and once daily before Day 6.&#xD;
&#xD;
        -  Group 1 received NALDEBAIN will evaluate injection site within 1 hour prior to dosing.&#xD;
&#xD;
      Study Day 0-5 All subjects will be given general anesthesia prior to their scheduled surgical&#xD;
      procedure.&#xD;
&#xD;
      If patients need additional medication for treatment of pain, Ketorolac and Morphine could be&#xD;
      used as supplemental analgesics when they needed.&#xD;
&#xD;
      After surgery, the following evaluations will be performed:&#xD;
&#xD;
        -  Pain assessment: All subjects will rate their average pain intensity using a VAS pain&#xD;
           scale. The assessment will perform before the first use of PCA or supplemental&#xD;
           analgesics and at 4±1, 24±2, 32±3, 48±4 hours and once daily on Days 3 to Day 5 after&#xD;
           the surgery.&#xD;
&#xD;
        -  Brief Pain Inventory (BPI) will be evaluated at Day 2.&#xD;
&#xD;
        -  Vital signs (temperature, respiratory rate, blood pressure and heart rate) will be&#xD;
           checked once daily before Day 6.&#xD;
&#xD;
        -  In Group 1 (NALDEBAIN group), the injection site will be evaluated once daily before&#xD;
           final visit.&#xD;
&#xD;
        -  Review of concomitant medication and adverse event record.&#xD;
&#xD;
        -  In Group 2 (PCA group), the amount of fentanyl used will be recorded on Days 0 through&#xD;
           2.&#xD;
&#xD;
      Study Day 6 Evaluate the following items at Day 6.&#xD;
&#xD;
        -  Pain assessment: Subjects will rate their pain intensity in the patient diary.&#xD;
&#xD;
        -  Brief Pain Inventory (BPI) will be evaluated.&#xD;
&#xD;
        -  Vital signs (temperature, respiratory rate, blood pressure and heart rate) will be&#xD;
           checked.&#xD;
&#xD;
        -  Injection site evaluation.&#xD;
&#xD;
        -  Review of the adverse event record.&#xD;
&#xD;
        -  Review of concomitant medication. Final Visit (Day of Discharge, Day 6~30)&#xD;
&#xD;
        -  Vital signs (temperature, respiratory rate, blood pressure and heart rate) will be&#xD;
           checked&#xD;
&#xD;
        -  Injection site evaluation&#xD;
&#xD;
        -  Laboratory tests, including hematological and biochemical tests, and urinalysis.&#xD;
&#xD;
        -  Patient satisfaction: At the final visit, each subject was asked the following question:&#xD;
           &quot;How satisfied were you with your postsurgical analgesia&quot;? Subjects were asked to&#xD;
           classify themselves as either &quot;highly satisfied&quot;, &quot;satisfied&quot;, &quot;uncertain&quot;,&#xD;
           &quot;dissatisfied&quot;, or &quot;very dissatisfied&quot;.&#xD;
&#xD;
        -  Physical examination.&#xD;
&#xD;
        -  Review of the adverse event record.&#xD;
&#xD;
        -  Review of concomitant medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain assessment (post-OP 48 hours)</measure>
    <time_frame>During post-OP 48 hours</time_frame>
    <description>Pain assessment (time-specific pain intensity) calculated as the area under the curve of VAS pain intensity scores through 48 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>supplemental analgesics</measure>
    <time_frame>From post-OP to Day 6</time_frame>
    <description>The consumption of total amount (mg) of supplemental analgesics administered after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment (post-OP to Day 6)</measure>
    <time_frame>From post-OP to Day 6</time_frame>
    <description>Pain assessment calculated as the area under the curve of VAS pain intensity scores through end of surgery to Day 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>pre-OP Day -1, post-OP Day 2 and Day 6</time_frame>
    <description>Pain intensity and interference of Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>On discharge Day, between post-OP Day 7 and Day 14</time_frame>
    <description>Patient satisfaction on a 5-point rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of postoperative hospital stay</measure>
    <time_frame>From post-OP to Discharge Day, about 1 to 2 weeks</time_frame>
    <description>Length of postoperative hospital stay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event</measure>
    <time_frame>From post-OP Day 1 to Discharge Day, about 1 to 2 weeks</time_frame>
    <description>Incidence of treatment-emergent adverse event (TEAE)</description>
  </other_outcome>
  <other_outcome>
    <measure>other abnormalities</measure>
    <time_frame>From Screening Day to Discharge Day, about 1 to 2 weeks</time_frame>
    <description>Percentage of abnormal from baseline to final visit in vital signs, laboratory tests and injection site evaluations.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Nalbuphine Sebacate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl Citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine Sebacate</intervention_name>
    <description>intramuscular single dose of NALDEBAIN 24±12 hours before surgery.</description>
    <arm_group_label>Nalbuphine Sebacate</arm_group_label>
    <other_name>NALDEBAIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Citrate</intervention_name>
    <description>Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.</description>
    <arm_group_label>Fentanyl Citrate</arm_group_label>
    <other_name>PCA with fentanyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female who is among 20 to 80 years of age at screening.&#xD;
&#xD;
          -  Scheduled to electively undergo open-laparotomy.&#xD;
&#xD;
          -  American Society of Anesthesiology Physical Class 1-3.&#xD;
&#xD;
          -  Ability and willingness to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index less than 18 kg/m2 or greater than 30 kg/m2.&#xD;
&#xD;
          -  History of previous open-laparotomy.&#xD;
&#xD;
          -  Surgery with major complication, or need blood transfusion.&#xD;
&#xD;
          -  History of hypersensitivity or adverse reaction to local anesthetics, opioid, or any&#xD;
             ingredient of the medications administered in this study.&#xD;
&#xD;
          -  Severe comorbidity.&#xD;
&#xD;
          -  Chronic preoperative opioid consumption.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Inability to use the PCA device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaw-Yuan Wang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ho Memorial Hospital, Kaohsiung Medical University:</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaw-Yuan Wang, PhD</last_name>
      <phone>+886-7-3121101</phone>
      <phone_ext>5575</phone_ext>
      <email>cy614112@ms14.hinet.net</email>
    </contact>
    <contact_backup>
      <last_name>Tsung-Kun Chang, MD</last_name>
      <phone>+886-7-3121101</phone>
      <phone_ext>5575</phone_ext>
      <email>tsungkunchang@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaw-Yuan Wang, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsung-Kun Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>September 23, 2017</last_update_submitted>
  <last_update_submitted_qc>September 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Jaw-Yuan Wang, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>post-laparotomy wound pain</keyword>
  <keyword>NALDEBAIN (150 mg Nalbuphine Sebacate)</keyword>
  <keyword>PCA (patient-control-ed alagesia)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

